TNFSF13B and systemic lupus erythematosus: Telitacicept binds to and neutralizes the activity of two cell signaling molecules, BLyS and a proliferation-inducing ligand (APRIL), thereby inhibiting the development and survival of plasma cells and mature B cells, and is also approved for the treatment of SLE (10).